Fluticasone Propionate
FDA-approved product (ointment, topical), marketed as Armonair Digihaler, Armonair Respiclick, Cutivate and 9 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Allergic rhinitis
- Asthma
- Atopic eczema
- Chronic bronchitis
- Chronic obstructive pulmonary disease
- Emphysema
- Nasal Cavity Polyp
- Nasal congestion
- Nasal polyposis
- Seasonal allergic rhinitis
- Skin disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids, potent (group iii); Corticosteroids; Glucocorticoids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Fluticasone Propionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
NCT00736801 · start 2005-09
Registered record
- Registry ID
- NCT00736801
- Conditions
- Allergic Asthma
- Interventions
- Salmeterol and Salmeterol / Fluticasone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2007-04
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAllergic AsthmaInterventionSalmeterol and Salmeterol / FluticasonePhaseNot applicableRegistry statusCompletedThe Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry
NCT00402207 · start 2005-08
Registered record
- Registry ID
- NCT00402207
- Conditions
- Asthma
- Interventions
- extrafine HFA-beclomethasone; HFA-fluticasone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-08
- Completion
- 2006-10
- Enrolment
- 33
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthmaInterventionextrafine HFA-beclomethasone; HFA-fluticasonePhaseNot applicableRegistry statusCompletedProtopic Ointment in Adult Atopic Eczema of the Face
NCT00690105 · start 2004-02
Registered record
- Registry ID
- NCT00690105
- Conditions
- Dermatitis, Atopic
- Interventions
- tacrolimus 0.1%; fluticasone 0.005 %
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-02
- Completion
- 2005-07
- Enrolment
- 577
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDermatitis, AtopicInterventiontacrolimus 0.1%; fluticasone 0.005 %PhasePhase 4Registry statusCompletedComparison of Two Treatment Regimens in Asthmatic Patients
NCT01488773 · start 1995-04
Registered record
- Registry ID
- NCT01488773
- Conditions
- Asthma
- Interventions
- first prescription of montelukast; first prescription of salmeterol
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 1995-04
- Completion
- 2006-06
- Enrolment
- 132
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthmaInterventionfirst prescription of montelukast; first prescription of salmeterolPhaseNot recordedRegistry statusCompletedExpanded Access Protocol for Patients With Eosinophilic Esophagitis
NCT05095116
Registered record
- Registry ID
- NCT05095116
- Conditions
- Eosinophilic Esophagitis
- Interventions
- APT-1011 3 mg HS
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- No longer available
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEosinophilic EsophagitisInterventionAPT-1011 3 mg HSPhaseNot recordedRegistry statusNo longer available